Early Assessment of the Efficacy of Temozolomide Chemotherapy in Experimental Glioblastoma Using [18F]FLT-PET Imaging

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Viel, Thomas ^a   Schelhaas, Sonja ^a   Wagner, Stefan ^b   Wachsmuth, Lydia ^b   Schwegmann, Katrin ^a   Kuhlmann, Michael ^a   Faber, Cornelius ^b   Kopka, Klaus ^c   Schäfers, Michael ^a,b   Jacobs, Andreas H ^a,d  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d Johanniter Krankenhaus   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE F 18; TEMOZOLOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SIZE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MONITORING; DRUG SENSITIVITY; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; TREATMENT DURATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BIOMARKERS, PHARMACOLOGICAL; BRAIN NEOPLASMS; DACARBAZINE; EARLY DIAGNOSIS; FEMALE; FLUORODEOXYGLUCOSE F18; GLIOBLASTOMA; HUMANS; INJECTIONS, INTRAVENTRICULAR; INJECTIONS, SUBCUTANEOUS; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME; TUMOR BURDEN;

MUS; MUS MUSCULUS;

EID: 84879816799     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067911     Document Type: Article

References (34)

1. Buckner JC, Brown PD, O'Neill BP, Meyer FB, Wetmore CJ, et al. (2007) Central nervous system tumours. Mayo Clin Proc 82: 1271-1286.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996.
4. Weller M. (2011) Novel diagnostic and therapeutic approaches to malignant glioma. Swiss Med Wkly 24; 141-148.
5. Silber JR, Bobola MS, Blank A, Chamberlain MC, (2012) O(6)-Methylguanine-DNA methyltransferase in glioma therapy: Promise and problems. Biochim Biophys Acta 1826: 71-82.
6. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, et al. (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003.
7. Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, et al. (2010) MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 6: 39-51.
8. Hermisson M, Klumpp A, Wick W, Wischhusen J, Nagel G, et al. (2006) O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem 96: 766-776.
9. Rueger MA, Ameli M, Li H, Winkeler A, Rueckriem B, et al. (2011) [18F]FLT PET for non-invasive monitoring of early response to gene therapy in experimental gliomas. Mol Imaging Biol 13: 547-557.
10. de Wit MC, de Bruin HG, Eijkenboom W, Sillevis Smitt PA, van den Bent MJ, (2004) Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 63: 535-537.
11. Kumar AJ, Leeds NE, Fuller GN, Van Tassel P, Maor MH, et al. (2000) Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology 217: 377-384.
12. Jacobs AH, Thomas A, Kracht LW, Li H, Dittmar C, et al. (2005) 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med 46: 1948-1958.
13. Ullrich RT, Kracht L, Brunn A, Herholz K, Frommolt P, et al. (2009) Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients with glioma. J Nucl Med 50: 1962-1968.
14. Waerzeggers Y, Monfared P, Viel T, Winkeler A, Jacobs AH, (2010) Mouse models in neurological disorders: applications of non-invasive imaging. Biochim Biophys Acta 1802: 819-839.
15. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, et al. (1998) Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4: 1334-1336.
16. Katz SI, Zhou L, Ferrara TA, Wang W, Mayes PA, et al. (2011) FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy. Int J Oncol 39: 91-100.
17. Wells P, Gunn RN, Alison M, Steel C, Golding M, et al. (2002) Assessment of proliferation in vivo using 2-[11C]thymidine positron emission tomography in advanced intra-abdominal malignancies. Cancer Res 62: 5698-5702.
18. Vesselle H, Grierson J, Muzi M, Pugsley JM, Schmidt RA, et al. (2002) In vivo validation of 3′deoxy-3′-[18F]fluorothymidine ([18F]FLT) as a proliferation imaging tracer in humans: correlation of [18F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 8: 3315-3323.
19. Buck AK, Bommer M, Stilgenbauer S, Juweid M, Glatting G, et al. (2006) Molecular imaging of proliferation in malignant lymphoma. Cancer Res 66: 11055-11061.
20. Ullrich R, Backes H, Li H, Kracht L, Miletic H, et al. (2008) Glioma proliferation as assessed by 3′-fluoro-3′-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma. Clin Cancer Res 14: 2049-2055.
21. Viel T, Talasila KM, Monfared P, Wang J, Jikeli JF, et al. (2012) Analysis of the growth dynamics of angiogenesis-dependent and-independent experimental glioblastomas by multimodal small-animal PET and MRI. J Nucl Med 53: 1135-1145.
22. Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, et al. (1994) A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 91: 7727-7731.
23. Abe T, Wakimoto H, Bookstein R, Maneval DC, Chiocca EA, et al. (2002) Intra-arterial delivery of p53-containing adenoviral vector into experimental brain tumors. Cancer Gene Ther 9: 228-235.
24. Machulla HJ, Blocher A, Kuntzsch M, Piert M, Wei R, et al. (2000) Simplified labeling approach for synthesizing 3′-deoxy-3′-[18F]fluorothymidine ([18F]FLT). J Radioanal Nucl Chem 24: 843-846.
25. Schäfers KP, Reader AJ, Kriens M, Knoess C, Schober O, et al. (2005) Performance evaluation of the 32-module quadHIDAC small animal PET scanner. J Nucl Med 46: 996-1004.
26. Vollmar SCJ (2004) VINCI- Volume imaging in neurological research, co-registration and ROIs included. In: Kremer K, Macho V, editors. Research and Scientific Computing 2003. Göttingen, Germany: Gesellschaft für wissenschaftliche Datenverarbeitung. 115-131.
27. Soloviev D, Lewis D, Honess D, Aboagye E, (2012) [18F]FLT: an imaging biomarker of tumour proliferation for assessment of tumour response to treatment. Eur J Cancer 48: 416-424.
28. Zhang CC, Yan Z, Li W, Kuszpit K, Painter CL, et al. (2012) [18F]FLT-PET imaging does not always "light up" proliferating tumor cells. Clin Cancer Res 18: 1303-1312.
29. Buck AK, Herrmann K, Shen C, Dechow T, Schwaiger M, et al. (2009) Molecular imaging of proliferation in vivo: positron emission tomography with [18F]fluorothymidine. Methods 48: 205-215.
30. Chen YL, Eriksson S, Chang ZF, (2010) Regulation and functional contribution of thymidine kinase 1 in repair of DNA damage. J Biol Chem 285: 27327-27335.
31. Galldiks N, Kracht LW, Burghaus L, Ullrich RT, Backes H, et al. (2010) Patient-tailored, imaging-guided, long-term temozolomide chemotherapy in patients with glioblastoma. Mol Imaging 9: 40-46.
32. Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, et al. (2012) 3′-deoxy-3′-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. J Nucl Med 53: 29-36.
33. Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, et al. (2007) Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F]fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 25: 4714-4721.
34. Wei LH, Su H, Hildebrandt IJ, Phelps ME, Czernin J, et al. (2008) Changes in tumor metabolism as readout for Mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma. Clin Cancer Res 14: 3416-3426.